Company intelligence / Profile preview
NeuroMax
Montpellier, France
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuroMax was a French biotechnology company focused on the discovery and development of neuroprotective small molecules for the treatment of neurodegenerative and neuromuscular diseases. Founded as a spin-off from the French National Institute of Health and Medical Research (INSERM), the company utilized its proprietary NeuroScreen platform to identify compounds that could prevent neuronal death. Its primary focus areas included Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). In 2005, NeuroMax was acquired by Trophos, another French biotech, which integrated NeuroMax's technology and pipeline into its own CNS-focused portfolio. Trophos was subsequently acquired by Roche in 2015.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
INSERMI-Stem
Beyond the preview
Go deeper on NeuroMax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroMax.